Law360, New York (February 10, 2015, 1:32 PM EST) -- Nobel laureates Georges Kohler and Cesar Milstein first reported the production of monoclonal antibodies in 1975.[1] Since that time, due to an alignment of technical, legal and regulatory factors, antibodies have become largely responsible for a golden age in the biopharma industry. Six new antibodies (vedolizumab, siltuximab, ramucirumab, pembrolizumab, nivolumab and blinatumomab) were approved by the U.S. Food and Drug Administration in 2014.[2] Thirty-five antibody species are now FDA-approved to treat a variety of conditions.[3] Tremendous opportunity in the industry is real and presents itself due to an alignment of technical, legal and regulatory factors....